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Interaction between tumour cells and stromal components is impor-
tant for the growth and invasion of a malignant tumour (Hauptmann
et al, 1995; Iozzo, 1995). Alterations in the stroma of epithelial
tumours involve the synthesis and degradation of extracellular matrix
components and cell adhesion and migration (Liotta et al, 1990; Hart
et al, 1992; Gui et al, 1995). Malignant tumours induce increased
synthesis of type I and III procollagens resembling that of poorly
controlled wound healing (Dvorak, 1986; Whalen, 1990). We have
earlier shown that progressive ovarian carcinoma induces a fibropro-
liferative response characterized by active expression of type I and III
procollagens (Zhu et al, 1993a, 1993b, 1995; Kauppila et al, 1996).
The fibre-forming type I and III collagens are synthesized as
precursors, procollagens, with propeptide domains at both ends
which are enzymatically cleaved off en bloc after their secretion
into the extracellular matrix (Birk et al, 1990). The collagen mole-
cules are incorporated into collagen fibres. The tensile strength of
these fibres is due to covalent cross-links between several mole-
cules within a fibre. The intermolecular cross-links are located in
the short, non-triple-helical terminal parts known as telopeptides.
The first reaction in cross-link formation is enzymatic, catalysed
by lysyl oxidase, and then several spontaneous reactions lead to
the formation of divalent cross-links, which mature into trivalent
cross-links. The collagen cross-links in soft tissues are fully
matured (Eyre et al, 1984; Yamauchi et al, 1988; Reiser et al,
1992). Interestingly, recent findings have shown that lysyl oxidase
is similar to the tumour suppressor protein know as rrg (Contente
et al, 1990; Kenyon et al, 1991) and its synthesis is decreased in
malignant breast tumour tissue (Peyrol et al, 1997).
In this study we have analysed the cross-linking processes of
type I and III collagen by analysing the collagen domains involved
in intermolecular cross-linking. Specific immunoassays were used
to measure the amount of the collagenous antigens directly in
neutral salt extracts and in the insoluble residua of benign and
malignant ovarian tumour tissues. In addition, the locations and
staining intensities of type I and III collagens were studied in these
samples by immunohistochemical (IHC) methods. We have been
able to show – for the first time – that the cross-link maturation is
defective in the malignant tissue in vivo.
MATERIALS AND METHODS
Tissue samples
Ovarian tumour tissue samples were obtained during operation
at the Department of Obstetrics and Gynaecology, Oulu
University Hospital. The diagnoses were based on histopatholog-
ical analyses carried out at the Department of Pathology. The
samples were frozen and stored at –20°C. Altogether 18 samples
of benign serous cystadenomas and malignant serous cystadeno-
carcinomas were used in this study. The study was approved by the
local Ethical Committee.
Immunoassays for type I and type III collagens
The characteristics of the quantitative immunoassays used in this
study are presented in Table 1. The concentrations of the type I
collagen antigens, ICTP and PINP, were measured separately in
duplicate by equilibrium radioimmunoassays (Orion Diagnostica,
FIN-90460 Oulunsalo, Finland) with methods described previ-
ously (Risteli et al, 1993; Melkko et al, 1996). The ICTP assay
detects trivalently cross-linked type I collagen in enzyme-digested
Cross-linked telopeptides of type I and III collagens in
malignant ovarian tumours in vivo
S Kauppila1, MK Bode1, F Stenbäck2, L Risteli1 and J Risteli1
Departments of 1Clinical Chemistry and 2Pathology, University of Oulu, FIN-90401 Oulu, Finland
Summary Malignant tumours often induce a fibroproliferative response in the adjacent stroma, characterized by increased expression of type
I and type III procollagens. In normal tissues, fibrillar collagens normally undergo extensive intermolecular cross-linking that provides tensile
strength to the tissue. Here we set out to characterize collagen cross-linking in human ovarian carcinoma tissue in vivo. Biochemical and
immunochemical methods were used for cross-linked telopeptides of type I and III collagens in samples of benign and malignant serous
tumours. The locations and staining patterns of these proteins were visualized immunohistochemically. The contents of both total collagen
and the cross-linked type I and type III collagens in the malignant samples were only about 20% of those in the benign tumours. The cross-
linked telopeptide antigens derived from the collagens were smaller and more heterogeneous in size in the malignant than in the benign
tumours, indicating a defective cross-linking process scarcely leading to the formation of mature cross-links in the collagen fibres in
malignancy. Immunostaining revealed disorganized type I and type III collagen bundles in carcinomas. These findings suggest that the
collagen cross-linking process is aberrant in malignant tumours, possibly resulting in increased susceptibility of tumour collagens for the
proteolysis often associated with tumour invasion. © 1999 Cancer Research Campaign
Keywords: collagen; ovarian neoplasms; invasion
654
British Journal of Cancer (1999) 81(4), 654–661
© 1999 Cancer Research Campaign
Article no. bjoc.1999.0743
Received 11 June 1998
Revised 15 February 1999
Accepted 10 March 1999
Correspondence to: J RisteliCollagen cross-linking in ovarian cancer 655
British Journal of Cancer (1999) 81(4), 654–661 © 1999 Cancer Research Campaign
tumour tissue, whereas the PINP assay was used to detect the
intact aminoterminal propeptide of type I procollagen and such
type I collagen that had retained aminoterminal propeptide (so-
called type I pN-collagen) in soluble tissue extracts. The intra- and
interassay coefficients of variation were 3–9% for PINP and 3–8%
for ICTP. PINP, representing the intact, trimeric aminoterminal
propeptide domain of type I procollagen, with a Mr of about
35 000, was measured in tumour extracts using dilutions 1:1 to
1:10, which gave a linear inhibition in the radioimmunoassay. The
ICTP concentrations were measured in enzyme-digested tumour
samples using dilutions varying from 1:10 to 1:10 000, the former
dilution for the malignant and the latter for the benign samples.
The PIIINP assay was used to detect the intact aminoterminal
propeptide of type III procollagen and type III pN-collagen in
soluble tumour tissue extracts. The concentration of PIIINP was
measured using an equilibrium radioimmunoassay giving intra-
and interassay coefficients of variation 4–5% (Orion Diagnostica)
(Risteli et al, 1988). The samples were diluted as for the PINP
assay. In addition, PIIINP analysis was applied to the enzyme-
digested tumour tissues.
The aminoterminal telopeptide of type III collagen, IIINTP, was
measured using a novel immunomethod (Bode et al, 1999) in
enzyme-digested tumour tissues. This method recognizes type III
collagen domains involved in intermolecular cross-linking of type
III collagen. The antigen was purified from human leiomyoma
using a combination of Sephacryl S-300 gel exclusion chromatog-
raphy and C18 reverse phase chromatography on HPLC. The puri-
fied antigen was sequenced, and its purity and molecular size
determined by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) and gel exclusion chromatography.
Polyclonal antibodies were raised in rabbits and one antiserum
was selected for this study (AS #68). The dilution of the antiserum
used in radioimmunoassay was 1:200, giving a 20% binding.
100 ml aliquots of a diluted sample were incubated with 200 ml of
diluted antiserum and 200 ml of 125I-IIINTP solution for 2 h at
37°C. Then, 0.5 ml of a solution of the solid-phase second anti-
body was added and the tubes were incubated at 4°C for 30 min.
They were centrifuged at 2000 g at 4°C for 30 min and the
radioactivity in the precipitate was counted.
Tissue preparation
For biochemical evaluation, the tissue samples of 0.4–3.6 g were cut
in small pieces and phosphate–buffered saline (PBS)–Tween was
added to 1 ml 100 mg–1 of wet tissue weight. The samples were
homogenized with an Ultra-Turrax homogenizer, cooled and let
stand on ice for 30 min. They were then centrifuged at 12 000 g for
20 min. The supernatants of the extracted tumour tissue were
collected for PINP and PIIINP analysis.
Test for effectiveness of trypsin digestion
Prior to the analysis of the clinical series, the conditions for
enzyme digestion were tested using both 0.1 mg and 1 mg trypsin
(TPCK) per 100 mg of wet tissue sample. The samples were heat-
denatured (+ 70°C for 1 h) and homogenized, and digestions were
performed at + 37°C for 6 h. Then the samples were re-denatured,
homogenized and retreated overnight with the same amount of
newly added trypsin. ICTP and IIINTP were measured in the
supernatant at different time points. The enzyme treatment was
found to release the antigens during the first 2 h, and the total anti-
genicity was not altered during the next 18 h and the successive
second enzyme treatment. Both concentrations of trypsin gave
similar total amounts of recovered ICTP and IIINTP antigens, and
the lower enzyme concentration was selected for further work.
Enzyme treatment of the clinical samples
The insoluble pellets were suspended in 0.2 M NH4HCO3
(1 ml 100 mg–1 of original wet tissue weight), denatured at + 70°C
for 1 h before enzyme treatment, and treated with 0.1 mg of
trypsin per 100 mg of the original wet tissue weight. Digestion
was performed at + 37°C for 4 h; then the samples were re-dena-
tured, homogenized and retreated with trypsin for another 4 h.
After that, the samples were centrifuged at 2000 g for 30 min. The
supernatants were used for ICTP, IIINTP and PIIINP analyses. For
the ratio of PIIINP and IIINTP, the 50% loss in PIIINP antigenicity
by trypsin treatment and the molecular sizes of both analytes were
taken into account (Bode et al, 1999). The total collagen content of
the tissue samples was measured by hydroxyproline analysis after
acid hydrolysis (Kivirikko et al, 1967).
Gel exclusion chromatography
Three trypsin-digested samples of benign disease and five of
malignant disease were analysed by gel filtration. Then, 2 ml
samples of the supernatants were applied to a Sephacryl S-100
column equilibrated in 0.2 M NH4HCO3 at room temperature, and
20-min fractions were collected with a flow rate of 5.4 ml h–1. The
apparent concentrations of ICTP, IIINTP and PIIINP were
measured with the immunoassays as described above using an
aliquot of the undiluted fraction or a 1:10 dilution. The fractions
Table 1 The immunoassays used for type I and type III collagen antigens
Assay Antibody raised against Immunochemical specificity Reference
ICTP Trivalently cross-linked Trivalently cross-linked carboxyterminal telopeptide of type I collagen, Risteli et al, 1993
carboxyterminal telopeptide of weak reaction with divalently cross-linked and non-cross-linked type I
human type I collagen collagen
IIINTP Aminoterminal telopeptide of Trivalently and divalently cross-linked type III collagen in tissue digests Bode et al, 1999
human type III collagen
PINP Intact aminoterminal propeptide Type I procollagen, type I collagen with retained aminoterminal Melkko et al, 1996
of human type I procollagen propeptide (= type I pN-collagen), intact aminoterminal propeptide
PIIINP Aminoterminal propeptide of Type III procollagen, type III collagen with retained aminoterminal Risteli et al, 1988
human type III procollagen propeptide (= type III pN-collagen), intact aminoterminal propeptide656 S Kauppila et al
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containing ICTP antigenicity and with the apparent molecular size
of the trypsin-digested trivalent ICTP structure were pooled,
freeze-dried and re-diluted in the volume of the original sample
applied to the column. This separation was necessary to reliably
estimate the content of mature, trivalent ICTP.
The supernatants of the extracted tumour tissues were also
analysed on a Sephacryl S-300 column equilibrated in PBS–Tween.
Twenty-minute fractions were collected with a flow rate of
6.0 ml h–1 and the concentrations of PINP and PIIINP were analysed
in the undiluted fractions with the immunoassays described.
IHC analysis
Altogether 13 specimens from the same ovarian tumour samples as
used above were obtained for IHC analysis. They included five
samples of benign serous cystadenomas and eight samples of
serous cystadenocarcinomas. The tissues were fixed in buffered
neutral formalin, embedded in paraffin and sectioned at 5 mm.
Immunohistochemical stainings were carried out using the
avidin–biotin–immunoperoxidase technique after pepsin digestion
(0.4% for 1–2 h at 37°C) as described previously in detail (Zhu
et al, 1993b, 1995). The sections were stained with specific
antibodies to the aminoterminal propeptides of type I and III
procollagens, anti-PINP and anti-PIIINP respectively. An antibody
to the cross-linked carboxyterminal telopeptide region of type I
collagen, anti-ICTP, was used to visualize the cross-linked type I
collagen fibres. These antibodies had been purified for IHC by
cross-adsorption with several extracellular matrix proteins, and
finally with the specific antigen in question coupled to CNBr-
activated Sepharose 4B. Lack of cross-reaction with other antigens
was tested by relevant radioimmuno-titration assays (Zhu et al,
1993b, 1995). The slides were counterstained with haematoxylin.
The localizations and staining intensities of the different antigens
in the tumour tissues were evaluated by a semi-quantitative scale
based on visual estimation.
Statistical analysis
Values are expressed as means (95% confidence intervals (CI)).
Statistical analysis was carried out using the SPSS statistical
analysis tool (for means and confidence intervals, and for
Spearman’s rank correlation analysis) and the CIA program for
confidence interval analysis (for confidence intervals, and for
Spearman’s rank correlation).
Table 2 Contents of cross-linked type I and III collagen antigens (ICTP and IIINTP), and hydroxyproline in trypsin-digested ovarian tumours
ICTP IIINTP Hydroxyproline
Cystadenomas 0.57 (0.44–0.71) mg g–1 0.58 (0.33–0.83) mg g–1 9.42 (5.63–13.21) mg g–1
(n = 8) 100% 100% 100%
Carcinomas 0.07 (0.04–0.11) mg g–1 0.10 (0.05–0.14) mg g–1 1.86 (0.94–2.75) mg g–1
(n = 10) 13% 17% 20%
The values present the mean (95% confidence intervals) as mg per tumour mass. The percentages indicate the relative values compared with cystadenomas.
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Figure 1 Gel filtration analysis of the cross-linked carboxyterminal telopeptides of type I collagen in enzyme digested tumour tissue. (A–C) Benign ovarian
cystadenoma; (D–F) malignant ovarian adenocarcinoma. The arrow indicates the elution position of the mature, trivalently cross-linked ICTP antigen and the
bar those of immature, divalently cross-linked and non-cross-linked forms of ICTP. Note the difference in the ICTP scales between the benign and the malignant
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RESULTS
Insoluble collagens in ovarian tumours
The cross-linked, and thus insoluble, forms of type I and type III
collagens were quantified by immunoassays that specifically
detect the terminal telopeptide domains of the respective mole-
cules containing a cross-link. Over 99% of the ICTP and IIINTP
antigenicities were detected in the insoluble tissue fractions, and
only 0.04–1% in the soluble form. The tissue contents of both
ICTP and IIINTP were lower in the malignant than in the benign
tissues. The benign cystadenomas showed an about 8 times higher
ICTP content than did the adenocarcinomas (mean 0.57 mg g–1
and 0.07 mg g–1 respectively, Table 2).
4-Hydroxyproline, the hydroxylated amino acid responsible for
the stability of the collagenous helix, makes up about 12% of the
mass of a fibrillar collagen molecule and can be used as a general
measure of the collagen content of a tissue. As expected, in the
ovarian tumours most of the hydroxyproline was recovered in the
insoluble fraction of the samples, with no difference between the
tumour types in this respect. However, the collagen contents of the
tissues varied greatly, with on the average 4.7 times more in the
benign tumours (7.9% w/w) than in the adenocarcinomas (1.7%
w/w) (Table 2).
The correlation between the hydroxyproline and ICTP contents
was 0.98 (P < 0.01, 95% CI 0.93–0.99) and that between the
hydroxyproline and IIINTP contents 0.96 (P < 0.01; 95% CI
0.88–0.98). There was also a strong correlation between ICTP and
IIINTP (r = 0.96; P < 0.01; 95% CI 0.89–0.99).
The amounts of type I and type III collagens can be estimated
from the contents of ICTP and IIINTP. In benign ovarian tissue the
proportion of type III collagen was 35% (29–42%) of the sum of
these collagens. Due to the defective cross-linking in type I
collagen, in malignant tumours in particular (see below), such an
estimate would not be accurate enough in carcinomas.
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Figure 2 Gel filtration analysis of the cross-linked aminoterminal
telopeptide of type III collagen in enzyme digested tumour tissue. (A) Benign
ovarian cystadenoma; (B) malignant ovarian adenocarcinoma. The first
arrow indicates the elution position of the mature, trivalently cross-linked
IIINTP and the second arrow that of immature, divalently cross-linked and
non-cross-linked forms of IIINTP. Note the difference in the IIINTP scales
between the benign and the malignant samples
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Figure 3 Gel filtration analysis of type I and III procollagen synthesis.
(A) PINP, (B) PIIINP in the soluble tissue extract of a malignant ovarian
tumour. The first arrow indicates the elution positions of type I or type III pN-
collagen, the second arrow that of the native aminoterminal propeptide of
type I or type III procollagen
Table 3 Contents of type III pN-collagen in trypsin-digested ovarian
tumours
PIIINP PIIINP/IIINTP
Cystadenomas 9.06 (6.11–12.01) mg g–1 0.007 (0.004–0.010)
(n = 8) 100% 100%
Carcinomas 5.59 (3.91–7.27) mg g–1 0.032 (0.020–0.044)
(n = 10) 62% 454%
The values present means (95% confidence intervals) as mg per tumour
mass or as a ratio. The percentages indicate the relative values compared
with cystadenomas. PIIINP = the aminoterminal propeptide of type III
procollagen, IIINTP = the cross-linked aminoterminal telopeptide of type III
collagen.658 S Kauppila et al
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Sizes of the cross-linked collagen antigens in digested
tumour tissue
The sizes of the cross-linked telopeptide antigens were studied by
gel filtration on Sepharose S-100 (Figures 1 and 2). In the benign
tumours the ICTP antigen eluted in one major peak (Figure 1 A–C)
corresponding in size to the trivalently cross-linked carboxyter-
minal telopeptide of type I collagen, as prepared by trypsin diges-
tion. In contrast, the same antigenicity from the malignant tumours
eluted mostly in two peaks with smaller molecular sizes, indi-
cating a decreased proportion of the trivalently cross-linked ICTP
AB
CD
EF
Figure 4 Immunohistochemical staining of type I pN-collagen: (A) benign tumour; (B) malignant tumour, cross-linked type I collagen: (C) benign tumour; (D)
malignant tumour, and type III pN-collagen; (E) benign tumour; (F) malignant tumour. Haematoxylin counterstain; original magnification, ´ 500Collagen cross-linking in ovarian cancer 659
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domains (Figure 1 D–F). After removal of these immature, diva-
lently cross-linked or non-cross-linked telopeptides, the decrease
in the content of the trivalent ICTP in malignant samples is even
more striking than in Table 2. The peak representing trivalent
ICTP was pooled from the gel filtration runs of five malignant
tumours, and the true ICTP content (mean 0.005 mg g–1) in these
pools was one-eighth of the apparent total ICTP content of the
same tumours, analysed directly in the digests (mean 0.04 mg g–1).
These findings altogether indicate an about 70-fold difference in
the content of trivalent ICTP between benign and malignant
tumours, which is much greater than the difference in the hydrox-
yproline contents between the two groups.
A similar phenomenon, although less marked, was seen for the
IIINTP antigen, which was heterogeneous both in the benign and
the malignant samples, but in which the proportion of the less
cross-linked species was larger in the carcinomas. Particularly in
the malignant samples, three peaks – most probably representing
trivalently and divalently cross-linked, and non-cross-linked forms
of the IIINTP telopeptide – could be observed (Figure 2).
Procollagen propeptides in ovarian tumour tissue
The aminoterminal propeptide domains of type I and III procolla-
gens, the PINP and PIIINP antigens respectively, were quantified
in the soluble fraction of the tissue samples. The mean PINP
concentrations were higher in the carcinoma samples than in the
benign tumours (2.45 (0.99–3.91) mg g–1 and 1.00 (0.51–1.50) mg
g–1 respectively). Since only about half of the carcinoma samples
had an increased PINP concentration, the difference between the
means was not statistically significant. For PIIINP, no such
tendency was evident between the benign and malignant tumours
(2.04 (0.88–3.20) mg g–1 and 1.44 (0.57–2.33) mg g–1 respectively).
PIIINP was also assessed in the trypsin digests of the insoluble
residues, whereas this was not possible for PINP because of the
trypsin sensitivity of its antigenic epitope. In fact, about 80% of
the PIIINP antigen was recovered in the insoluble fraction. There
was no difference, however, between the total PIIINP contents in
the benign and malignant tumours (Table 3). Since the PIIINP and
IIINTP were assayed in the same samples, it is possible to estimate
what part of type III collagen molecules retains the aminoterminal
propeptide. In the benign tumours this was 0.7% (0.4–1.0) and in
the malignant ones 3.2% (2.0–4.4) (Table 3).
Sizes of the procollagen propeptide antigens in ovarian
tumours
The soluble PINP and PIIINP antigens were characterized by gel
filtration on Sepharose S-300. For both the benign and the malig-
nant tumours, the major PINP peak eluted at a volume of 134–
150 mL, which is the elution position of the intact, free trimeric
aminoterminal propeptide of type I procollagen (Figure 3A). The
majority of the PIIINP antigen, in contrast, eluted at 94–108 ml,
corresponding to type III pN-collagen (Figure 3B). Again, there
were only minor differences between the benign and the malignant
samples.
IHC studies of type I and III collagens
The following monospecific antibodies were used for visualizing
the extracellular matrix structures in IHC: anti-PINP, to show type
I pN-collagen; anti-ICTP, to show mature, cross-linked type I
collagen; and anti-PIIINP, to show type III pN-collagen, which is
present on the surface of practically all type III collagen fibres. In
the benign tumours, all the type I and III collagen antigens had the
appearance of regularly distributed collagen bundles (Figure 4 A,
C and E). In the malignant tumours, both the staining intensities
and the apparent distributions of the collagen bundles were more
irregular (Figure 4 B, D and F).
Type I collagen staining, both for PINP and ICTP, was positive
in all specimens. Type I pN-collagen staining was evident at the
epithelial–stromal junction (Figure 4A) in all but one specimen.
The more distant stroma stained only weakly in most of these
specimens. Mature cross-linked type I collagen was seen both in
the stroma adjacent to the epithelium and in the distant stroma of
benign tumours (Figure 4C). In the poorly differentiated malignant
tumours, aberrant PINP staining was seen in the vicinity of malig-
nant cells (Figure 4B). The ICTP staining was slightly weaker in
these areas (Figure 4D).
Type III pN-collagen was present at the epithelial–stromal junc-
tion in both the benign and the malignant tumours, often staining
the collagen bundles in the normal appearing distant stroma
(Figure 4E). In the stroma adjacent to the tumour cells its staining
intensity varied from non-existent to strong. The difference
between the staining intensities in the adjacent and distant stromas
was less evident than for either of the type I collagen antigens.
DISCUSSION
The total collagen content of the ovarian tissue was clearly lower
in the malignant than in the corresponding benign tumours studied
here. A similar difference was evident for the telopeptide domains
of both major fibrillar collagen species. However, there was also a
distinct qualitative difference between the telopeptide antigens of
the benign and malignant tumour tissues, the latter containing
remarkably less of the trivalently cross-linked ICTP and IIINTP
antigens (Table 2).
Collagen fibres are responsible for the tensile strength of soft
tissues. To fulfil this function, the individual rod-like molecules
must be chemically cross-linked to their neighbours within the
collagen fibril (Eyre et al, 1984; Yamauchi et al, 1988; Reiser et al,
1992). The cross-linking process involves a number of partially
alternative reactions and in soft tissues normally leads to the
formation of mature, trivalent cross-links within a relatively short
time (Cronlund et al, 1985; Eyre et al, 1984). Only the first reac-
tion in the collagen cross-linking pathway is catalysed by an
enzyme, lysyl oxidase, whose expression by the fibroblasts gener-
ally parallels their collagen expression (Feres-Filho et al, 1996;
Fushida-Takemura et al, 1996; Desmouliere et al, 1997). Despite
the low collagen content in ovarian carcinoma tissue, the synthesis
rates of both type I and III collagens are increased, as indicated in
this study by the procollagen propeptide concentrations and by our
previous in situ hybridization study (Kauppila et al, 1996). Thus
there should be enough collagen substrate for the lysyl oxidase
enzyme. Interestingly, it has recently been reported that lysyl
oxidase expression is very low in breast carcinoma tissue (Peyrol
et al, 1997) and that it is similar to the tumour suppressor protein
rrg (Contente et al, 1990; Kenyon et al, 1991). Our finding of a
defective collagen cross-linking process is in agreement with the
assumption that the lack of this enzyme activity could be a general
phenomenon in invading carcinomas. The disrupted collagen
bundles visualized by our immunostainings could also be a result
of defective cross-linking.Since the telopeptide cross-links in benign ovarian tissues are
fully matured, the total amounts of type I and III collagens can be
reliably estimated from their contents of ICTP and IIINTP. Our
results indicate that type III collagen makes up 35% of the sum of
the type I and III collagens, which is about the same percentage,
for example, as previously estimated for rat liver tissue by
different methods (Kelley et al, 1984).
Collagen fibril formation takes place in the extracellular space
immediately after the release of these proteins from the fibroblasts.
The aminoterminal procollagen propeptides have been suggested to
regulate the fibril formation (Fleischmajer et al, 1985). Our gel
filtration findings confirm that the aminoterminal propeptide of type
III procollagen frequently remains attached to the collagen mole-
cule, whereas a significant part of the corresponding propeptide of
type I procollagen is found in a free, cleaved form. In IHC this
difference is supported by the fact that staining with anti-PIIINP
antibodies can be usually detected throughout the stroma in benign
tissue, whereas the PINP staining is mostly present in the junctional
area next to the epithelium, where collagen synthesis is the most
active. Interestingly, the relative amount of PIIINP when expressed
over IIINTP in the insoluble matrix is 4.5-fold higher in the malig-
nant than in the benign situation (Table 3), indicating an increased
amount of newly synthesized type III collagen.
Although there needs not be a major difference in the tensile
strength between the collagen fibres containing either divalent or
trivalent cross-links (Eyre et al, 1984) such a difference can have
other important effects. In irreversible fibroses of the liver and the
skin (Ricard-Blum et al, 1993, 1996) the collagen contains more
trivalent cross-links with the pyridinoline structure than does the
collagen of the corresponding normal tissue. In this respect,
ovarian carcinoma represents an opposite fibroproliferative situa-
tion with its decreased content of trivalently cross-linked colla-
gens. It seems probable that defective cross-linking makes the
collagens more susceptible for the degrading enzymes. This
together with increased extracellular proteolysis in carcinomas,
confirmed by several studies (Laiho et al, 1989; Van der Stappen et
al, 1990; Aznavoorian et al, 1993; Stetler-Stevenson et al, 1993a,
1993b; Furcht et al, 1994; Stetler-Stevenson, 1996) could promote
tumour invasion. The prognostic value of the defective collagen
cross-linking in ovarian cancer remains to be elucidated, together
with the possible presence of this phenomenon in other cancers.
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